To include your compound in the COVID-19 Resource Center, submit it here.

Lucentis ranibizumab regulatory update

The U.K.'s NICE and the Scottish Medicines Consortium recommended against the use of Lucentis ranibizumab from Novartis to treat diabetic macular edema (DME). NICE issued a final appraisal

Read the full 285 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE